Advances in the Treatment of Cognitive Impairment in Schizophrenia: Targeting NMDA Receptor Pathways
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms251910668 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Ting Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Health Science Center, Ningbo University, Ningbo 315211, China. Hauptthemen laut MEDLINE: Schizophrenia, Receptors, N-Methyl-D-Aspartate, Cognitive Dysfunction. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 168 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Zhejiang Province, National Natural Science Foundation of China, Young Doctor Innovation Research Program of Ningbo.
Abstract (Originalsprache)
Cognitive impairment is a core feature of schizophrenia, playing a pivotal role in the pathogenesis and prognosis of this disorder. Cognitive impairment in schizophrenia encompasses a wide range of domains, including processing speed, episodic memory, working memory, and executive function. These deficits persist throughout the course of the illness and significantly impact functional outcomes and quality of life. Therefore, it is imperative to identify the biological basis of cognitive deficits in schizophrenia and develop effective treatments. The role of N-methyl-D-aspartate (NMDA) receptors in synaptic transmission and plasticity has long been recognized, making them potential targets for schizophrenia treatment. This review will focus on emerging pharmacology targeting NMDA receptors, offering strategies for the prevention and treatment of cognitive deficits in schizophrenia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Health Science Center, Ningbo University, Ningbo 315211, China.
ORCID-Profile: Chang Liu, Ning Zhong, Xiaoqin Zhang
Förderung
- Natural Science Foundation of Zhejiang Province
- National Natural Science Foundation of China
- Young Doctor Innovation Research Program of Ningbo
- Municipal Key R&D Program of Ningbo
- 111 Project of China
Zitieren
APA
Zhang, T., Liu, C., Zhong, N., Wang, Y., Huang, Y., & Zhang, X. (2024). Advances in the Treatment of Cognitive Impairment in Schizophrenia: Targeting NMDA Receptor Pathways. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms251910668
Vancouver
Zhang T, Liu C, Zhong N, Wang Y, Huang Y, Zhang X. Advances in the Treatment of Cognitive Impairment in Schizophrenia: Targeting NMDA Receptor Pathways. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms251910668
BibTeX
@article{Zhang2024,
author = {Zhang, Ting and Liu, Chang and Zhong, Ning and Wang, Yichen and Huang, Yiyun and Zhang, Xiaoqin},
title = {Advances in the Treatment of Cognitive Impairment in Schizophrenia: Targeting NMDA Receptor Pathways},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms251910668}
}
EUVIMED